Dr. Joan Fallon, Founder & CEO of Curemark, Named One of the 2016 PM360 Elite 100
RYE, NY (PRWEB) June 02, 2016 -- PM360, the premier information resource for marketing decision makers in the pharmaceutical and medical device sectors, has named Dr. Joan Fallon, founder & CEO of Curemark, as one of the 2016 PM360 ELITE 100. Now in its second year, the PM360 ELITE (Exceptional • Leaders • Innovators • Transformers • Entrepreneurs) represent the most influential people in the healthcare industry today.
“Being recognized as one the PM360 ELITE 100 most influential people in healthcare is truly an honor,” says Dr. Fallon. “However, the honor actually belongs to the families of the children with Autism. Curemark’s work is inspired by these children and their families and they are our focus as we continue our research and progress our ongoing Phase III clinical trial.”
Dr. Fallon is a specialist in pediatric development and has been at the forefront of research for autism and other related disorders. Curemark is currently conducting a Phase III clinical trial for Autism at over 25 sites across the United States, called the Blüm™ Study. Curemark's Autism drug, CM-AT, has been given "Fast Track" designation by FDA and was granted a rolling review of its New Drug Application (NDA) for CM-AT. Dr. Fallon has written numerous scholarly articles, and has lectured around the world on developmental problems in the pediatric population.
The PM360 ELITE Awards were established in 2015 to recognize individuals who have made a significant impact to the healthcare industry throughout their careers. This year, the awards were expanded to include Marketing Teams as well as individuals. More than 500 submissions were received and nominees were evaluated based on their accomplishments; testimonials from their bosses, clients, and colleagues; and supporting evidence that reflects the impact of their efforts (i.e., company growth, campaign success, etc.). A total of 100 winners were selected across 16 categories, including Creative Directors, Data Miners, Digital Crusaders, Disrupters, Drug Researchers and Developers, Entrepreneurs, Launch Experts, Leaders of the Future, Marketing Teams, Master Educators, Mentors, Patient Advocates, Sales MVPs, Strategists, Tech-know Geeks, and Transformational Leaders.
“Each of the 100 individuals and teams selected truly demonstrated that they have left their mark on this industry,” says Anna Stashower, CEO and Publisher of PM360. “Whether it was from a career worth of accomplishments or a single initiative that changed how things are done, each of them is deserving of being called ELITE.”
Dr. Joan Fallon and the rest of the winners will be honored at a celebratory event on July 12th in New York City.
About Curemark
Curemark, LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Curemark’s pipeline includes preclinical and clinical-stage programs for the treatment of Autism, ADHD, addiction, Schizophrenia and Parkinson’s disease. For additional information, please visit http://www.curemark.com or follow @curemark on Twitter.
About CM-AT
CM-AT, Curemark’s lead drug candidate, has been granted “Fast Track” designation by the U.S. Food and Drug Administration for the investigation of Autism. The company is currently enrolling a Phase III double blind, randomized, placebo-controlled clinical trial (known as the Blüm Study) to examine the effect of CM-AT in children ages 3-8 with Autism. The trial is enrolling in over 25 sites across the United States. For additional information, please see: http://www.blumstudy.com.
About PM360
PM360 is the premier, must-read magazine for marketing decision makers in the pharmaceutical, biotech, and medical device industries. Published monthly, PM360 is the only journal that focuses on delivering the full spectrum of practical information necessary for product managers and pharmaceutical marketing professionals to succeed in the complex and highly regulated healthcare environment.
Shay Pantano, Rubenstein PR, +1 212-805-3062, [email protected]
Share this article